Relapsed Pulmonary Cryptococcosis during Tumor Necrosis Factor α Inhibitor Treatment
| Autor: | Yoshifumi Imamura, Naofumi Suyama, Katsunori Yanagihara, Hiroshi Kakeya, Tomomi Saijo, Takahiro Takazono, Kazuko Yamamoto, Toyomitsu Sawai, Hiroshi Mukae, Taiga Miyazaki, Shigeru Kohno, Masato Tashiro, Koichi Izumikawa |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Adult Male medicine.medical_specialty Antifungal Agents 030106 microbiology Case Report Gastroenterology 03 medical and health sciences Biological agents 0302 clinical medicine Crohn Disease Internal medicine Internal Medicine medicine Humans Pulmonary cryptococcosis 030212 general & internal medicine Relapse Tumor necrosis factor α Fluconazole Lung Diseases Fungal business.industry Tumor Necrosis Factor-alpha Clinical course General Medicine Cryptococcosis Infliximab humanities Immunology Tumor necrosis factor α inhibitor business medicine.drug |
| Zdroj: | Internal Medicine |
| ISSN: | 0918-2918 |
| Popis: | A 35-year-old non-HIV patient developed pulmonary cryptococcosis after the initiation of infliximab. He recovered by fluconazole treatment and completed the therapy for a total of 6 months. However, he experienced a relapse 16 months later during retreatment with infliximab, revealing an interesting clinical course contradicting retreatment. This case also represents the first case of relapsed pulmonary cryptococcosis suspected during treatment with a biologic agent. Both of these aspects generated important clinical questions about the length of pulmonary cryptococcosis treatment and the necessity of introducing a second prophylaxis for such patients. Internal Medicine, 55(19), pp.2877-2880; 2016 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|